CERo Therapeutics (CERO) announced that investigators have been authorized under the study protocol to administer a third infusion of CER-1236 to a patient enrolled in the first cohort of its ongoing ...
Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...
CERo Therapeutics (CERO) dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid leukemia. Per protocol, three patients are planned at ...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback